Stocks
Alterity Therapeutics LimitedATHE
NASDAQHealthcareBiotechnology$2.37
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing therapies for neurodegenerative diseases, including a lead candidate for multiple system atrophy and Parkinson's disease. Its pipeline targets iron accumulation in the brain, a mechanism that differentiates it from other neurology-focused biotechs. Investors track ATHE for its upcoming clinical trial readouts and its potential to address an unmet medical need in rare neurological disorders.
52W Range: $2.35-$5.89
Congressional Interest in Alterity Therapeutics Limited (ATHE)
No congressional trades have been disclosed for Alterity Therapeutics Limited (ATHE) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading ATHE?
No congressional trades found for this stock.